Polymer polyglycolic acid is biocompatible in the body. A needle-shaped long-acting anti-cancer preparation (F-PGA needle) was prepared by compounding polyglycolic acid and the anti-cancer drug 5-Fluorouracil (5-FU). The release of 5-FU from the needle was maintained for about 10 days, and the needle disappeared after one year. A clinical study with the F-PGA needle was made on patients with terminal carcinomas. Shrinkage of tumors and tumor necrosis were observed in two patients with metastatic liver carcinomas. The F-PGA needle supplies high-dose 5-FU locally for a long time with fewer side effects by embedding it into the tumor tissue. Therefore the F-PGA needle can be said to be promising in the treatment of unresectable cancer as a topical application of chemotherapy.
Download full-text PDF |
Source |
---|
Nihon Geka Gakkai Zasshi
December 1984
The purpose of these studies was to characterize the effect of the new anticancer preparation, 5-fluorouracil-polyglycolic acid-composite (F-PGA needle), on experimental tumors and in patients with solid tumors. The formative composite in a F-PGA needle was found to easily dissociate in physiologic saline resulting in the release of 5-fluorouracil (5-FU). The aspect of 5-FU release was observed to be relative to 5-FU content in the needle, but not to the length of the needle.
View Article and Find Full Text PDFGan To Kagaku Ryoho
August 1984
Polymer polyglycolic acid is biocompatible in the body. A needle-shaped long-acting anti-cancer preparation (F-PGA needle) was prepared by compounding polyglycolic acid and the anti-cancer drug 5-Fluorouracil (5-FU). The release of 5-FU from the needle was maintained for about 10 days, and the needle disappeared after one year.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!